Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Incyte Corporation (INCY)

59.33   -1.04 (-1.72%) 09-21 12:50
Open: 60.24 Pre. Close: 60.37
High: 60.38 Low: 59.1
Volume: 819,010 Market Cap: 13,295(M)

Technical analysis

as of: 2023-09-21 12:17:25 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 73.47     One year: 76.63
Support: Support1: 58.54    Support2: 48.7
Resistance: Resistance1: 62.9    Resistance2: 65.61
Pivot: 62.7
Moving Average: MA(5): 60.45     MA(20): 63.16
MA(100): 63.56     MA(250): 71.34
MACD: MACD(12,26): -1.1     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 22     %D(3): 19.9
RSI: RSI(14): 31.2
52-week: High: 86.29  Low: 58.54
Average Vol(K): 3-Month: 1,523 (K)  10-Days: 1,932 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ INCY ] has closed above bottom band by 1.8%. Bollinger Bands are 50.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 61.08 - 61.37 61.37 - 61.67
Low: 59.41 - 59.79 59.79 - 60.16
Close: 59.67 - 60.27 60.27 - 60.86

Company Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Headline News

Wed, 20 Sep 2023
Incyte Co. Reports Strong Second Quarter Earnings and Increased ... - Best Stocks

Tue, 19 Sep 2023
How Does Incyte Corporation (INCY) Stock Rank on Wall Street Tuesday? - InvestorsObserver

Tue, 19 Sep 2023
Pancreatic Cancer Battle Boosted by $200M VC Firm - Incyte (NASDAQ:INCY), BioNTech (NASDAQ:BNTX) - Benzinga

Tue, 19 Sep 2023
Incyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug - Nasdaq

Mon, 18 Sep 2023
Anemia Advantage For GSK's Blood Cancer Therapy Could ... - UK

Mon, 18 Sep 2023
Relative Strength Alert For Incyte - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 223 (M)
Shares Float 187 (M)
% Held by Insiders 1.4 (%)
% Held by Institutions 99.4 (%)
Shares Short 5,950 (K)
Shares Short P.Month 5,730 (K)

Stock Financials

EPS 1.63
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 21.22
Profit Margin (%) 10.4
Operating Margin (%) 12.7
Return on Assets (ttm) 4.8
Return on Equity (ttm) 8.3
Qtrly Rev. Growth 4.6
Gross Profit (p.s.) 7.12
Sales Per Share 15.73
EBITDA (p.s.) 2.34
Qtrly Earnings Growth 25
Operating Cash Flow 781 (M)
Levered Free Cash Flow 739 (M)

Stock Valuations

PE Ratio 36.13
PEG Ratio 1.2
Price to Book value 2.79
Price to Sales 3.76
Price to Cash Flow 16.92

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.